NeuroOne Medical Technologies Corporation (NMTC) Income Statement
NMTC FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsNMTC revenue and net income
Where NMTC's revenue goes
FY2025Each bar shows an amount and its share of revenue. NMTC kept −29.8% of revenue as net income.
NMTC profit margins
NMTC growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +250.4% | +313.5% | +44.4% | +162.7% |
| Gross profit | +654.1% | — | +34.4% | +152.5% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NMTC quarterly EPS vs estimates
NeuroOne Medical Technologies beat the analyst EPS estimate in 5 of the last 8 quarters.
NMTC income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $3.5M | $2.0M | $171,169 | $178,146 | $1.9M | $0 | $0 | $0 | $742 |
| Cost of revenue | $4.0M | $2.4M | $1.5M | $241,963 | $275,895 | $70,552 | $27,569 | $21,667 | $7,740 | $0 |
| Gross profit | $8.1M | $1.1M | $456,517 | −$70,794 | −$97,749 | $1.9M | −$27,569 | −$21,667 | −$7,740 | $742 |
| Research & development | $5.0M | $5.1M | $6.9M | $4.9M | $3.9M | $2.1M | $1.5M | $951,064 | $735,333 | $735,333 |
| Sales, general & admin | $7.4M | $7.9M | $6.8M | $6.7M | $6.3M | $4.8M | $4.3M | $3.2M | $32,611 | $49,587 |
| Total operating expenses | $12.4M | $13.0M | $12.4M | $10.0M | $10.1M | $6.8M | $5.8M | $3.2M | $32,611 | $30,915 |
| Operating income | −$4.2M | −$11.9M | −$12.0M | −$10.0M | −$10.2M | −$4.9M | −$5.8M | −$3.2M | −$32,611 | −$30,915 |
| Interest expense | $334,063 | $228,988 | $0 | $31,152 | $3,053 | $7.5M | $284,557 | $1.4M | $0 | $14,018 |
| Income before taxes | −$3.6M | −$12.3M | −$11.9M | −$10.0M | −$9.9M | −$13.6M | −$6.8M | −$6.8M | −$32,611 | −$30,915 |
| Income taxes | — | — | $31,371 | −$109,865 | $274,175 | $7.5M | $284,557 | $3 | $15,164 | $31,948 |
| Net income | −$3.6M | −$12.3M | −$11.9M | −$10.0M | −$9.9M | −$13.6M | −$6.8M | −$6.8M | −$47,775 | −$62,863 |
| EBITDA | −$3.0M | −$11.8M | −$11.7M | −$9.9M | −$9.9M | −$4.9M | −$5.8M | −$4.1M | −$14,978 | −$30,915 |
| EPS (diluted) | −$0.27 | −$1.16 | −$3.25 | −$3.33 | −$1.20 | −$0.91 | −$0.58 | −$1.10 | −$2.27 | −$0.14 |
| Gross margin | 67.3% | 31.3% | 23.4% | −41.4% | −54.9% | 96.3% | — | — | — | 100.0% |
| Operating margin | −34.9% | −344.3% | −612.3% | −5,860.2% | −5,735.9% | −254.5% | — | — | — | −4,166.4% |
| Net margin | −29.8% | −356.7% | −607.4% | −5,842.0% | −5,584.3% | −708.0% | — | — | — | −8,472.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $2.4M | $2.9M | $2.7M | $1.7M | $1.4M | $3.3M | $272,284 | $825,776 | $1.4M | $977,649 | $741,780 |
| Cost of revenue | $790,496 | $1.1M | $1.3M | $1.2M | $781,215 | $615,489 | $1.3M | $131,222 | $543,904 | $986,875 | $711,335 | $548,125 |
| Gross profit | $1.2M | $1.3M | $1.6M | $1.5M | $914,835 | $771,061 | $1.9M | $141,062 | $281,872 | $390,419 | $266,314 | $193,655 |
| Research & development | $1.4M | $1.5M | $1.4M | $1.1M | $1.2M | $1.5M | $1.2M | $1.1M | $1.2M | $1.3M | $1.5M | $1.8M |
| Sales, general & admin | $2.2M | $1.9M | $1.9M | $1.8M | $1.6M | $1.9M | $2.0M | $2.0M | $1.9M | $2.0M | $2.2M | $1.6M |
| Total operating expenses | $3.6M | $3.4M | $3.3M | $2.9M | $2.8M | $3.5M | $215,682 | $3.0M | $3.1M | $3.3M | $3.7M | $3.4M |
| Operating income | −$2.4M | −$2.1M | −$1.7M | −$1.4M | −$1.9M | −$2.7M | $1.7M | −$2.8M | −$2.8M | −$2.9M | −$3.4M | −$3.2M |
| Interest expense | $0 | $0 | $0 | $334,063 | $9,325 | $0 | $324,738 | $228,988 | $0 | $0 | $0 | — |
| Income before taxes | −$2.0M | −$2.1M | −$1.4M | −$1.6M | −$1.5M | −$2.3M | $1.8M | −$3.4M | −$2.8M | −$2.9M | −$3.3M | −$3.1M |
| Income taxes | — | — | — | — | — | — | $1.8M | — | $3 | — | $3 | $18,697 |
| Net income | −$2.0M | −$2.1M | −$1.4M | −$1.6M | −$1.5M | −$2.3M | $1.8M | −$3.4M | −$2.8M | −$2.9M | −$3.3M | −$3.1M |
| EBITDA | −$2.0M | −$2.0M | −$1.4M | −$1.6M | −$1.4M | −$2.2M | $2.2M | −$3.0M | −$2.7M | −$2.8M | −$3.3M | −$3.1M |
| EPS (diluted) | −$0.28 | −$0.25 | −$0.18 | −$0.03 | −$0.18 | −$0.42 | $0.36 | −$0.11 | −$0.10 | −$0.11 | −$0.84 | −$0.13 |
| Gross margin | 59.9% | 53.8% | 54.2% | 55.8% | 53.9% | 55.6% | 58.9% | 51.8% | 34.1% | 28.3% | 27.2% | 26.1% |
| Operating margin | −122.9% | −87.9% | −59.0% | −50.0% | −111.2% | −193.3% | 52.3% | −1,034.5% | −338.3% | −209.5% | −346.8% | −426.6% |
| Net margin | −101.7% | −87.2% | −49.7% | −59.1% | −88.5% | −163.8% | 54.5% | −1,230.6% | −335.1% | −207.3% | −342.1% | −422.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NMTC's financial statements (latest annual report filed December 17, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NMTC financial results
In fiscal year 2025 (ended September 30, 2025), NeuroOne Medical Technologies reported revenue of $12.1 million, up 250.4% from the year before. It had a net loss of $3.6 million, a net profit margin of −29.8%. Diluted earnings per share came to −$0.27. Over five years revenue grew at an average rate of 44.4% a year.
See the NMTC stock overview for the latest quote and news, or the NMTC chart for price history and technical indicators.
NMTC income statement FAQ
What is NeuroOne Medical Technologies's annual revenue?
NeuroOne Medical Technologies reported total revenue of $12.1 million for fiscal year 2025, which ended on September 30, 2025. That was up 250.4% from $3.5 million the previous year.
Is NeuroOne Medical Technologies profitable?
No. NeuroOne Medical Technologies reported a net loss of $3.6 million in fiscal 2025, a net profit margin of −29.8%; its operating margin was −34.9%.
What is NeuroOne Medical Technologies's gross margin?
NeuroOne Medical Technologies's gross margin was 67.3% in fiscal 2025: for every $100 of revenue, NeuroOne Medical Technologies kept $67 after the direct cost of its products and services.
How much does NeuroOne Medical Technologies spend on research and development?
NeuroOne Medical Technologies spent $5.0 million on research and development in fiscal 2025, 41.2% of revenue.
How fast is NeuroOne Medical Technologies growing?
Revenue grew 44.4% a year on average over the last five fiscal years, from $1.9 million to $12.1 million.
What are NeuroOne Medical Technologies's earnings per share?
NeuroOne Medical Technologies earned $-0.27 per diluted share in fiscal 2025, compared with $-1.16 a year earlier.
When does NeuroOne Medical Technologies's fiscal year end?
NeuroOne Medical Technologies's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on December 17, 2025.